Dss, Inc 10-Q for FY2025 Q2

Dss, Inc. (DSS)

10-Q 2025-08-14 For: 2025-06-30

Added on April 10, 2026

About this 10-Q

Dss, Inc filed this 10-Q on August 14, 2025, covering the quarter ended June 30, 2025 (FY2025 Q2).

Headline figures

Quarter ended June 30, 2025, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $5.29M; up 25.5% from $4.21M a year earlier
Net loss: $2.61M; compared with a net loss of $4.95M a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

Title of each class		Ticker symbol(s)		Name of each exchange on which registered
Common Stock, $0.02 par value per share		DSS		The NYSE American LLC

PART I	FINANCIAL INFORMATION
Item 1
	Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 (unaudited)	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 (Unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited)	5
	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the six months ended June 30, 2025 and 2024 (Unaudited)	6
	Notes to Interim Condensed Consolidated Financial Statements (Unaudited)	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 4	Controls and Procedures	34

PART II	OTHER INFORMATION	35
Item 1	Legal Proceedings	35
Item 1A	Risk Factors	35
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3	Defaults upon Senior Securities	35
Item 4	Mine Safety Disclosures	35
Item 5	Other Information	35
Item 6	Exhibits	35

	June 30, 2025			December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$	9,384,000		$	11,431,000
Restricted cash		100,000			-
Accounts receivable, net		2,688,000			3,068,000
Inventory, net		2,543,000			2,442,000
Marketable securities		2,974,000			2,442,000
Assets held for sale		-			45,158,000
Current portion of notes receivable, net		-			240,000
Current portion of notes receivable - related party, net		305,000			337,000
Current portion of notes receivable		305,000			337,000
Prepaid expenses and other current assets		889,000			1,141,000
Total current assets		18,883,000			66,695,000

Property, plant and equipment, net		5,141,000			5,381,000
Investments in real estate, net		35,446,000			-
Other investments		500,000			500,000
Investment, equity method		124,000			129,000
Marketable securities		6,791,000			6,333,000
Notes receivable, net		-			17,000
Notes receivable - related party, net		-			112,000
Notes receivable		-			112,000
Other assets		964,000			162,000
Right-of-use assets		6,135,000			6,465,000
Goodwill		1,769,000			1,769,000
Other intangible assets, net		17,640,000			18,890,000
Total assets	$	93,393,000		$	106,453,000

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	2,506,000		$	2,793,000
Accrued expenses and deferred revenue		2,616,000			2,651,000
Other current liabilities		4,537,000			4,193,000
Current portion of lease liability		593,000			606,000
Current portion of long-term debt, net		42,964,000			642,000
Current portion of long-term debt on assets held-for-sale, net		-			53,534,000
Current portion of long-term debt - related party, net		616,000			609,000
Current portion of long-term debt		616,000			609,000
Total current liabilities		53,832,000			65,028,000

Long-term debt, net		6,172,000			2,398,000
Long term lease liability		6,011,000			6,311,000
Total liabilities		66,015,000			73,737,000

Commitments and contingencies (Note 12)		-			-

Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2024); *Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2024).		-			-
Common stock, $.02 par value; 200,000,000 shares authorized, 9,092,518 shares issued and outstanding on June 30, 2025 (8,092,518 on December 31, 2024)		182,000			161,000
Additional paid-in capital		325,488,000			323,150,000
Accumulated deficit		(310,001,000	)		(303,072,000	)
Total stockholders’ equity of the Company		15,669,000			20,239,000
Non-controlling interest in subsidiaries		11,709,000			12,477,000
Total stockholders’ equity		27,378,000			32,716,000

Total liabilities and stockholders’ equity	$	93,393,000		$	106,453,000

	2025			2024			2025			2024
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2025			2024			2025			2024
Revenue:
Printed products	$	4,272,000		$	3,527,000		$	8,255,000		$	6,599,000
Rental income		715,000			438,000			1,429,000			838,000
Net investment income		9,000			41,000			29,000			136,000
Commission revenue		282,000			204,000			503,000			507,000
Biotechnology retail sales		7,000			1,000			21,000			2,000
Total revenue		5,285,000			4,211,000			10,237,000			8,082,000

Costs and expenses:
Cost of revenue		5,499,000			5,673,000			10,685,000			10,663,000
Selling, general and administrative (including stock based compensation)		3,211,000			3,473,000			6,703,000			7,035,000
Total costs and expenses		8,710,000			9,146,000			17,388,000			17,698,000
Operating loss		(3,425,000	)		(4,935,000	)		(7,151,000	)		(9,616,000	)

Other income (expense):
Interest income		25,000			195,000			33,000			302,000
Other income		1,000			12,000			10,000			38,000
Interest expense		(123,000	)		(142,000	)		(156,000	)		(190,000	)
Foreign Currency Translation Adjustment		3,000			(9,000	)		-			(14,000	)
(Loss)/gain on equity method investment		(2,000	)		8,000			(5,000	)		7,000
Gain (loss) on investments		1,557,000			(383,000	)		627,000			(572,000	)
Impairment of intangible assets		(600,000	)		-			(600,000	)		-
Provision for loan losses		-			(53,000	)		-			(346,000	)
(Loss)/gain on sale		(43,000	)		165,000			(727,000	)		165,000
Loss from operations before income taxes		(2,607,000	)		(5,142,000	)		(7,969,000	)		(10,226,000	)

Income tax benefit		-			188,000			67,000			163,000
Net loss	$	(2,607,000	)	$	(4,954,000	)	$	(7,902,000	)	$	(10,063,000	)

Loss from operations attributed to noncontrolling interest		455,000			271,000			973,000			1,309,000

Net loss attributable to DSS common stockholders	$	(2,152,000	)	$	(4,683,000	)	$	(6,929,000	)	$	(8,754,000	)

Loss per common share attributable to common stockholders
Basic	$	(0.24	)	$	(0.66	)	$	(0.78	)	$	(1.24	)
Diluted	$	(0.24	)	$	(0.66	)	$	(0.78	)	$	(1.24	)

Shares used in computing loss per common share:
Basic		9,092,518			7,066,772			8,889,221			7,066,772
Diluted		9,092,518			7,066,772			8,889,221			7,066,772

	2025			2024
Cash flows from operating activities:
Net loss	$	(7,902,000	)	$	(10,063,000	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization		1,058,000			1,136,000
Issuance of common stock for bonus		870,000			-
Stock based payments for professional services rendered		190,000			-
Stock based payments		4,000			-
(Loss)/gain on equity method investment		5,000			(7,000	)
Loss (gain) on investments		303,000			572,000
Change in ROU assets		330,000			369,000
Change in inventory obsolescence		(21,000	)		-
Accrued interest on notes payable		1,884,000			-
Loss (Gain) on sale of assets		250,000			(165,000	)
Impairment of intangibles		600,000			-
Provision for loan losses		235,000			815,000
Decrease (increase) in assets:
Accounts receivable		380,000			1,679,000
Inventory		(80,000	)		(753,000	)
Assets held for sale		(38,000	)		-
Prepaid expenses and other current assets		241,000			504,000
Other assets		(802,000	)		(42,000	)
Increase (decrease) in liabilities:
Accounts payable		(287,000	)		(224,000	)
Accrued expenses		(26,000	)		(529,000	)
ROU liabilities		(313,000	)		(339,000	)
Other liabilities		3,549,000			1,473,000
Net cash provided (used) by operating activities		430,000			(5,574,000	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(144,000	)		(29,000	)
Sale of real estate		9,500,000			-
Purchase of marketable securities		(1,000,000	)		-
Purchase of investment		-			(379,000	)
Disposal of property, plant and equipment		-			5,140,000
Sale of investment, related party		1,500,000			-
Sale of marketable securities		116,000			-
Payments received on notes receivable		163,000			4,044,000
Net cash provided by investing activities		10,135,000			8,776,000

Cash flows from financing activities:
Payments of long-term debt		(9,443,000	)		(1,269,000	)
Borrowings of long-term debt		109,000			2,171,000
Payments on margin loan		(3,178,000	)		-
Net cash (used) provided by financing activities		(12,512,000	)		902,000

Net increase (decrease) in cash		(1,947,000	)		4,104,000
Cash and cash equivalents at beginning of period		11,431,000			6,615,000

Cash and cash equivalents at end of period	$	9,484,000		$	10,719,000

	Shares		Amount		Shares		Amount		in Capital		Deficit			Equity			Subsidiary			Total
	Common Stock				Preferred Stock				Additional Paid-		Accumulated			Total DSS			Non- controlling Interest in
	Shares		Amount		Shares		Amount		in Capital		Deficit			Equity			Subsidiary			Total

Balance, December 31, 2023		7,067,772	$	140,000		-	$	-	$	319,963,000	$	(256,176,000	)	$	63,927,000		$	19,286,000		$	83,213,000
															-
Net loss		-		-		-		-		-		(8,754,000	)		(8,754,000	)		(1,309,000	)		(10,063,000	)
Balance, June 30, 2024 (unaudited)		7,067,772	$	140,000		-	$	-	$	319,963,000	$	(264,930,000	)	$	55,173,000		$	17,977,000		$	73,150,000

Balance, December 31, 2024		8,092,518	$	161,000		-	$	-	$	323,150,000	$	(303,072,000	)	$	20,239,000		$	12,477,000		$	32,716,000
Balance		8,092,518	$	161,000		-	$	-	$	323,150,000	$	(303,072,000	)	$	20,239,000		$	12,477,000		$	32,716,000

Issuance of common stock, net of expenses - Impact BioMedical, Inc.		-		1,000		-		-		1,294,000		-			1,295,000			205,000			1,500,000
Issuance of common stock for bonus		1,000,000		20,000		-		-		850,000		-			870,000			-			870,000
Stock based payments for professional services rendered for Impact Bio		-		-		-		-		190,000		-			190,000			-			190,000
Stock based payments		-		-		-		-		4,000		-			4,000			-			4,000
Net loss		-		-		-		-		-		(6,929,000	)		(6,929,000	)		(973,000	)		(7,902,000	)
Balance, June 30, 2025 (unaudited)		9,092,518	$	182,000		-	$	-	$	325,488,000	$	(310,001,000	)	$	15,669,000		$	11,709,000		$	27,378,000
Balance		9,092,518	$	182,000		-	$	-	$	325,488,000	$	(310,001,000	)	$	15,669,000		$	11,709,000		$	27,378,000

	June 30, 2025			December 31, 2024
Finished Goods	$	1,719,000		$	1,857,000
Work in Process		100,000			345,000
Raw Materials		861,000			420,000
Inventory gross	$	2,680,000			2,622,000
Less allowance for obsolescence		(137,000	)		(180,000	)
Inventory net	$	2,543,000		$	2,442,000

	June 30, 2025
	cost		Unrealized Gain/(Loss)			Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	8,151,000	$	-		$	8,151,000	$	8,151,000	$	-
Restricted Cash		100,000		-			100,000		100,000		-
Level 1
Money Market Funds		1,233,000		-			1,233,000		1,233,000		-
Marketable Securities		27,816,000		(18,051,000	)	$	9,765,000		-		9,765,000
Total	$	37,300,000	$	(18,051,000	)	$	19,249,000	$	9,484,000	$	9,765,000

	December 31, 2024
	Adjusted Cost		Unrealized Gain/(Loss)			Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	11,369,000	$	-		$	11,369,000	$	11,369,000	$	-
Level 1						$	-
Money Market Funds	$	62,000	$	-		$	62,000	$	62,000	$	-
Marketable Securities	$	25,933,000	$	(16,722,000	)	$	9,211,000	$	-	$	9,211,000
Total	$	37,364,000	$	(16,722,000	)	$	20,642,000	$	11,431,000	$	9,211,000

Year	Notes payable		Notes payable - related party		Total
2025	$	36,717,000	$	616,000	$	37,333,000
2026		902,000		-		902,000
2027		947,000		-		947,000
2028		995,000		-		995,000
2029		494,000		-		494,000
Thereafter		3,206,000		-		3,206,000
Total	$	43,261,000	$	616,000	$	43,877,000

	Totals
2025	$	421,000
2026		839,000
2027		808,000
2028		824,000
2029		840,000
Thereafter		4,074,000
Total lease payments		7,806,000
Less: Imputed Interest		(1,202,000	)
Present value of remaining lease payments	$	6,604,000

Current	$	593,000
Noncurrent	$	6,011,000

Weighted-average remaining lease term (years)		9.1

Weighted-average discount rate		3.8	%

	2025		2024

Cash paid for interest	$	1,963,000	$	501,000

Non-cash investing and financing activities:
Shares issued in lieu of bonus cash	$	870,000	$	-
Shares issued in lieu of cash as payment for legal services	$	190,000	$	-
Stock based compensation	$	4,000	$	-

Three Months Ended June 30, 2025	Product Packaging			Commercial Lending			Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	4,288,000		$	9,000		$	-		$	7,000		$	981,000		$	-		$	5,285,000
Cost of revenue		4,094,000			234,000			(7,000	)		13,000			1,165,000			-			5,499,000
Gross profit (loss)		194,000			(225,000	)		7,000			(6,000	)		(184,000	)		-			(214,000	)
Operating expense		754,000			75,000			34,000			1,024,000			737,000			426,000			3,050,000
Operating income (loss)		(560,000	)		(300,000	)		(27,000	)		(1,030,000	)		(921,000	)		(426,000	)		(3,264,000	)
Other income (expense)		(37,000	)		(170,000	)		(7,000	)		3,000			107,000			922,000			818,000
Net income (loss) from continuing operations before taxes		(597,000	)		(470,000	)		(35,000	)		(1,027,000	)		(814,000	)		496,000			(2,607,000	)

Three Months Ended June 30, 2024	Product Packaging			Commercial Lending			Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	3,539,000		$	44,000		$	3,000		$	1,000		$	624,000		$	-		$	4,211,000
Cost of revenue		3,598,000			-			-			9,000			2,066,000			-			5,673,000
Gross profit (loss)		(59,000	)		44,000			3,000			(8,000	)		(1,442,000	)		-			(1,462,000	)
Operating expense		823,000			120,000			94,000			663,000			998,000			775,000			3,473,000
Operating income (loss)		(882,000	)		(76,000	)		(91,000	)		(671,000	)		(2,440,000	)		(775,000	)		(4,935,000	)
Other income (expense)		(29,000	)		578,000			195,000			3,000			(127,000	)		(827,000	)		(207,000	)
Net income (loss) from continuing operations before taxes		(911,000	)		502,000			104,000			(668,000	)		(2,567,000	)		(1,602,000	)		(5,142,000	)

Six Months Ended June 30, 2025	Product Packaging			Commercial Lending			Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	8,286,000		$	30,000		$	-		$	21,000		$	1,900,000		$	-		$	10,237,000
Cost of Revenue		7,895,000			212,000			(7,000	)		24,000			2,561,000			-			10,685,000
Gross profit (loss)		391,000			(182,000	)		7,000			(3,000	)		(661,000	)		-			(448,000	)
Operating expense		1,464,000			140,000			68,000			2,080,000			899,000			1,891,000			6,542,000
Operating income (loss)		(1,073,000	)		(322,000	)		(61,000	)		(2,083,000	)		(1,560,000	)		(1,891,000	)		(6,990,000	)
Other income (expense)		(75,000	)		(416,000	)		(1,000	)		46,000			(970,000	)		598,000			(818,000	)
Net loss from continuing operations		(1,148,000	)		(738,000	)		(62,000	)		(2,037,000	)		(2,530,000	)		(1,293,000	)		(7,969,000	)

Six Months Ended June 30, 2024	Product Packaging			Commercial Lending			Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	6,620,000		$	146,000		$	3,000		$	2,000		$	1,311,000		$	-		$	8,082,000
Cost of revenue		6,365,000			469,000			-			19,000			3,810,000			-			10,663,000
Gross profit (loss)		255,000			(323,000	)		3,000			(17,000	)		(2,499,000	)		-			(2,581,000	)
Operating expense		1,547,000			234,000			154,000			1,467,000			2,122,000			1,511,000			7,035,000
Operating income (loss)		(1,292,000	)		(557,000	)		(151,000	)		(1,484,000	)		(4,621,000	)		(1,511,000	)		(9,616,000	)
Other income (expense)		(75,000	)		(324,000	)		186,000			(126,000	)		(284,000	)		13,000			(610,000	)
Net income (loss) from continuing operations		(1,367,000	)		(881,000	)		35,000			(1,610,000	)		(4,905,000	)		(1,498,000	)		(10,226,000	)

Three months ended June 30, 2025
Packaging Printing and Fabrication	$	4,150,000
Commercial and Security Printing		122,000
Real Property Rental Income		16,000
Total Printed Products	$	4,288,000

Three months ended June 30, 2024
Packaging Printing and Fabrication	$	3,434,000
Commercial and Security Printing		87,000
Real Property Rental Income		18,000
Total Printed Products	$	3,539,000

Six months ended June 30, 2025
Packaging Printing and Fabrication	$	7,966,000
Commercial and Security Printing		257,000
Real Property Rental Income		32,000
Total Printed Products	$	8,255,000

Six months ended June 30, 2024
Packaging Printing and Fabrication	$	6,287,000
Commercial and Security Printing		278,000
Real Property Rental Income		34,000
Total Printed Products	$	6,599,000

Three months ended June 30, 2025
Retail internet sales	$	7,000
Total Biotechnology	$	7,000

Three months ended June 30, 2025
Rental income	$	699,000
Commission income	$	282,000
Total Rental Income	$	981,000

	●	LineBacker: Multi-faceted therapeutic platform for metabolic, neurologic, cancer, and infectious diseases.

	●	Equivir: A polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir/Nemovir technology is a novel blend of FDA Generally Recognized as Safe (“GRAS”) eligible polyphenols (e.g., Myricetin, Hesperetin, Piperine) which have demonstrated antiviral effects with additional potential application as health supplements or medication. Polyphenols are sourced from fruits, vegetables, and other natural substances. Myricetin is a member of the flavonoid class of polyphenolic compounds with antioxidant properties. Hesperitin is a flavanone and Piperine is an alkaloid, commonly found in black pepper.

	●	Procombin: Applications as food additive, and natural preservative for beauty and person care products as well as natural food preservative.

	●	VanXin: Food preservative booster made up of polyphenols that extend the shelf life.

	●	Bioplastics: Advanced bio-compatible plastics that mitigate accumulation of plastics in oceans and landfills and provide UVA and UVB protection for many types of material for including containers, hard surfaces, and fibers for clothing. The technology is presently in development and testing antimicrobial plastics for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus, by exploiting key strategies found in the biological realm. These new plastics are specifically focused on solutions for common products such as cups, plates, utensils, plastic bags, and countertops. The first prototypes are currently undergoing antimicrobial resistance testing.

	●	Laetose: Laetose technology is derived from a unique combination of sugar and inositol, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. A sugar alternative which is believed to lower human glycemic indexes and is believed to be a breakthrough alternative sugar aimed to combat diabetes. The use of Laetose in a daily diet, compared to sugar, could result in 30% lower sugar consumption and lower glycemic index/load.

	●	3F: A botanical compound believed to serve as an insect repellent and anti-microbial agent. 3F is a unique formulation of specialized ingredients (e.g. terpenes) from botanical sources with demonstrated effect as an insect repellent and an antimicrobial.

	●	3F Mosquito Repellent: 3F repellent contains botanical ingredients that mosquitos avoid. These ingredients are scientifically proven1 to affect the mosquito’s receptors, essentially making the insect blind to a human’s presence. This can be utilized as a stand-alone repellent or as an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection.

	●	3F Antimicrobial: 3F antimicrobial contains botanical ingredients known to kill viruses. These ingredients are scientifically proven to inhibit viral replication. This can be utilized as a stand-alone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics, and other substances.

	●	Quantum: The solution to the Patent Cliff accomplished by creating a new class of medicinal chemistry that uses advanced methods to increase effectiveness and persistence of natural compounds and existing drugs. The safety attributes of the original molecules are maintained. Typically, drug discovery processes modify functional groups. Quantum’s new techniques alter behavior of molecules at the sub-molecular level. It is estimated that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Quantum and these methods can be used to enhance and patent natural compounds including many substances used in traditional medicines around the world.

	●	Bio Med (license): A probiotic gut health product that helps to regulate many physiological functions, ranging from energy regulation and cognitive processes to toxin neutralization and immunity against pathogens.

	●	REIT Management Fund: In March 2020, DSS Securities formed AMRE (“American Medical REIT”) and its management company AAMI (“AMRE Asset Management, Inc.) Through AAMI/AMRE, a medical real estate investment trust, fulfills community needs for quality healthcare facilities while enabling care providers to allocate their capital to growth and investment in their contemporary clinical and critical care businesses. Urban and suburban communities are in need of modern healthcare facilities that provide a range of medical outpatient services. The funds ultimate product is an investor opportunity in a managed medical real estate investment trust.

	●	Sentinel: Sentinel primarily operates as a financial intermediary, facilitating institutional trading of municipal and corporate bonds as well as preferred stock, and accelerates the trajectory of the DSS digital securities business.

	●	BMIC: BMIC is a private investment bank specializing in corporate finance advising, raising equity, and venture services, providing a global “one-stop” corporate consultancy to listed companies. From corporate finance to professional valuation, corporate communications to event management, BMIC services companies in the US, Hong Kong, Singapore, Taiwan, Japan, Canada, and Australia.

	●	DSS Wealth Management: AmericaFirst is a suite of mutual funds managed by DSS Wealth Management. AmericaFirst expects to expand into numerous investment platforms including additional mutual funds and exchange-traded funds. AmericaFirst currently consists of four mutual funds that seek to outperform their respective benchmark indices by applying top-down, fundamental research, quantitative and technical analysis to stock selection and portfolio management.

	Three months ended June 30, 2025		Three months ended June 30, 2024		% Change			Six months ended June 30, 2025		Six months ended June 30, 2024		% Change
Product Packaging	$	4,288,000	$	3,536,000		21	%	$	8,287,000	$	6,633,000		25	%
Securities		981,000		626,000		57	%		1,900,000		1,311,000		45	%
Commercial Lending		9,000		48,000		-81	%		29,000		136,000		-79	%
Biotechnology		7,000		1,000		600	%		21,000		2,000		950	%

	$	5,285,000	$	4,211,000		26	%	$	10,237,000	$	8,082,000		27	%

Exhibit Number		Exhibit Description

3.1		Certificate of Incorporation *

3.2		Certificate of Incorporation of Document Security Systems, Inc., as amended (incorporated by reference to exhibit 3.1 to Form 8-K dated August 25, 2016).

3.3		Fifth Amended and Restated Bylaws *

10.1		Securities Purchase Agreement between Decentralized Sharing Systems, Inc. and Sharing Services Global Corporation for the sale of HWH Holdings, Inc. (incorporated by reference to exhibit 10.1 to exhibit 10.1 to the Company’s quarterly report, dated August 13, 2024)

10.2		Securities Purchase Agreement between Decentralized Sharing Systems, Inc. and Sharing Services Global Corporation for the sale of HWH World, Inc. (incorporated by reference to exhibit 10.2 to exhibit 10.1 to the Company’s quarterly report, dated August 13, 2024)

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. *

31.2		Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer. *

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. *

32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. *

101.INS		Inline XBRL Instance Document*
101.SCH		Inline XBRL Taxonomy Extension Schema Document*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)*

	DSS, INC.

August 14, 2025	By:	/s/ Jason Grady
		Jason Grady
		Interim Chief Executive Officer
		(Principal Executive Officer)

August 14, 2025	By:	/s/ Todd D. Macko
		Todd D. Macko
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.